Radius Files IPO, Aims for $86 Million

CAMBRIDGE, MA, Feb 07, 2012 (MARKETWIRE via COMTEX) -- Radius Health, Inc., a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and other women’s health conditions, today announced that it has filed a registration statement with the Securities and Exchange Commission relating to a proposed public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. All the proposed shares in the offering will be sold by Radius Health, Inc.

UBS Investment Bank and Leerink Swann LLC are acting as joint book-running managers and underwriters for the proposed offering. Cowen and Company, LLC and Rodman & Renshaw, LLC are serving as co-managers for the proposed offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective.

When available, copies of the preliminary prospectus relating to the proposed offering may be obtained by contacting UBS Investment Bank, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, (888) 827-7275, or Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, (800) 808-7525, ext. 4814.

SOURCE: Radius Health, Inc.